4 резултати
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the psychoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
FIELD OF THE INVENTION
The present invention relates to novel therapeutics and pharmaceutical compositions including J-series prostaglandin-ethanolamides, and methods of using and administering the same.
BACKGROUND OF THE INVENTION
There are two major types of skin cancer, non-melanoma skin cancer